{"title":"替诺福韦-阿拉非那胺用于治疗新发慢性乙型肝炎：单中心回顾性研究","authors":"Cihan Semet","doi":"10.54962/ankemderg.1413377","DOIUrl":null,"url":null,"abstract":"Chronic hepatitis B (CHB) is a major global health problem affecting approximately 257 million people worldwide. Tenofovir alafenamide (TAF) is a new, effective antiviral drug for chronic hepatitis B. However, real-world data on the efficacy of TAF in treating naive patients are limited. This study aimed to evaluate TAF's efficacy in treating naive CHB patients. Factors associated with virological response and alanine aminotransferase (ALT) normalization were also analyzed in the study. The study included 41 treatment-naive CHB patients who started TAF between January 2021 and December 2022. Demographic, clinical, and laboratory data were collected at baseline and week 48. The primary endpoints were complete virologic response (CVR) and ALT normalization at week 48. At week 48, ALT and hepatitis B virus-deoxyribonucleic acid (HBV DNA) levels decreased to statistically significant levels (both p","PeriodicalId":505102,"journal":{"name":"ANKEM Dergisi","volume":"83 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tenofovir Alafenamide in the Treatment of Naïve Chronic Hepatitis B: A Single-Centre Retrospective Study\",\"authors\":\"Cihan Semet\",\"doi\":\"10.54962/ankemderg.1413377\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chronic hepatitis B (CHB) is a major global health problem affecting approximately 257 million people worldwide. Tenofovir alafenamide (TAF) is a new, effective antiviral drug for chronic hepatitis B. However, real-world data on the efficacy of TAF in treating naive patients are limited. This study aimed to evaluate TAF's efficacy in treating naive CHB patients. Factors associated with virological response and alanine aminotransferase (ALT) normalization were also analyzed in the study. The study included 41 treatment-naive CHB patients who started TAF between January 2021 and December 2022. Demographic, clinical, and laboratory data were collected at baseline and week 48. The primary endpoints were complete virologic response (CVR) and ALT normalization at week 48. At week 48, ALT and hepatitis B virus-deoxyribonucleic acid (HBV DNA) levels decreased to statistically significant levels (both p\",\"PeriodicalId\":505102,\"journal\":{\"name\":\"ANKEM Dergisi\",\"volume\":\"83 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ANKEM Dergisi\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.54962/ankemderg.1413377\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ANKEM Dergisi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54962/ankemderg.1413377","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
慢性乙型肝炎（CHB）是影响全球约 2.57 亿人健康的重大全球性健康问题。替诺福韦-阿拉非那胺（TAF）是一种新型、有效的慢性乙型肝炎抗病毒药物。本研究旨在评估 TAF 治疗初治慢性乙型肝炎患者的疗效。研究还分析了与病毒学应答和谷丙转氨酶（ALT）正常化相关的因素。该研究纳入了41名在2021年1月至2022年12月期间开始接受TAF治疗的治疗无效的CHB患者。在基线和第48周收集了人口统计学、临床和实验室数据。主要终点是第48周时的完全病毒学应答（CVR）和ALT正常化。第 48 周时，ALT 和乙型肝炎病毒脱氧核糖核酸（HBV DNA）水平降至统计学意义上的显著水平（均为 p
Tenofovir Alafenamide in the Treatment of Naïve Chronic Hepatitis B: A Single-Centre Retrospective Study
Chronic hepatitis B (CHB) is a major global health problem affecting approximately 257 million people worldwide. Tenofovir alafenamide (TAF) is a new, effective antiviral drug for chronic hepatitis B. However, real-world data on the efficacy of TAF in treating naive patients are limited. This study aimed to evaluate TAF's efficacy in treating naive CHB patients. Factors associated with virological response and alanine aminotransferase (ALT) normalization were also analyzed in the study. The study included 41 treatment-naive CHB patients who started TAF between January 2021 and December 2022. Demographic, clinical, and laboratory data were collected at baseline and week 48. The primary endpoints were complete virologic response (CVR) and ALT normalization at week 48. At week 48, ALT and hepatitis B virus-deoxyribonucleic acid (HBV DNA) levels decreased to statistically significant levels (both p
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
